specialty pharmacies are responsible for distributing therapies to the patient on behalf of the manufacturer, so they need a centralised application to support the entire process of patient intake ...

The clerical overhead of enrolment forms navigated ... efficient copay assistance programs to understand the patient journey in depth. Cost: technology should reduce program overhead.

Eligible patients in the U.S. who are prescribed Niktimvo have access to IncyteCARES (Connecting to Access, Reimbursement, Education and Support), a comprehensive program offering personalized patient ...

During 2024, we successfully advanced every clinical program in our portfolio ... of myelofibrosis (MF), demonstrating robust and broad hematologic activity across patient segments Results showed ...

FDG PET SUVR projected onto the cortical surface (left hemisphere) for (from left to right) a cognitively normal subject (CN), a patient with ... and from the Contrat d'Interface Local program (to OC) ...

and the new headwind in the form of Medicare Part D benefit design which represents an additional headwind AbbVie needs to absorb. The pipeline is also progressing nicely. There are five new ...

AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid ...

Two years after AbbVie’s loss of market exclusivity for Humira, those “How it Started and How it’s Going” memes are looking better each quarter for the Illinois drugmaker. On Friday ...

Well before the market open, news broke of those two AbbVie price target increases. They came at the kickoff of the week, when the company was scheduled to post its fourth-quarter earnings (on ...

Jamie Kelter Davis / Bloomberg via Getty Images AbbVie's fourth-quarter revenue exceeded forecasts on higher sales of its Skyrizi and Rinvoq drugs to treat inflammation. The demand for those two ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

AbbVie Q4 adjusted EPS of $2.16 beat estimates, with strong sales of Skyrizi (+57.9%) and Rinvoq (+47.1%) boosting revenue growth. AbbVie raises 2027 revenue forecast for Skyrizi and Rinvoq to $31 ...